Implementing injectable opioid agonist treatment: a survey of professionals in the field of opioid use disorders

References

• Bansback, N., Guh, D., Oviedo-Joekes, E., Brissette, S., Harrison, S., Janmohamed, A., Krausz, M., MacDonald, S., Marsh, D. C., Schechter, M. T., & Anis, A. H. (2018). Cost-effectiveness of hydromorphone for severe opioid use disorder: Findings from the SALOME randomized clinical trial. Addiction (Abingdon, England), 113(7), 1264–1273. https://doi.org/10.1111/add.14171
   PubMed Web of Science ®Google Scholar
• Bell, J., Belackova, V., & Lintzeris, N. (2018). Supervised injectable opioid treatment for the Management of Opioid Dependence. Drugs, 78(13), 1339–1352. https://doi.org/10.1007/s40265-018-0962-y
   PubMed Web of Science ®Google Scholar
• Brisson, P. (2011). Les personnes qui utilisent des drogues par injection (UDI). In R. Parent (Ed.), Centre d’expertise et de référence en santé publique (INSPQ). https://www.inspq.qc.ca/sites/default/files/documents/itss/fiche-udi.pdf
   Google Scholar
• British Columbia Ministry of Health (2017). Guidance for: Injectable opioid agonist treatment for opioid use disorder. British Columbia Centre on Substance Use. https://www.bccsu.ca/wp-content/uploads/2017/10/BC-iOAT-Guidelines-10.2017.pdf
   Google Scholar
• Canadian Research Initiative on Substance Misuse (CRISM) (2018). CRISM National Guideline for the Clinical Management of Opioid Use Disorder. https://crism.ca/wp-content/uploads/2018/03/CRISM_NationalGuideline_OUD-ENG.pdf
   Google Scholar
• Canadian Research Initiative in Substance Misuse (CRISM). (2019). National injectable opioid agonist treatment for opioid use disorder clinical guideline. https://crism.ca/projects/ioat-guideline/
   Google Scholar
• Cedarbaum, E. R., & Banta-Green, C. J. (2016). Health behaviours of young adult heroin injectors in the Seattle Area. Drug and Alcohol Dependence, 158, 102–109. https://doi.org/10.1016/j.drugalcdep.2015.11.011
   PubMed Web of Science ®Google Scholar
• Chou, R., Korthuis, P. T., Weimer, M., Bougastsos, C., Blazina, I., Zakher, B., Grusing, S., Devine, B., & McCarty, D. (2016). Medication-assisted treatment models of care for opioid use disorder in primary care settings (Report No. 16(17)-EHC039-EF). Agency for Healthcare Research and Quality (US). https://www.ncbi.nlm.nih.gov/books/NBK402352/
   Google Scholar
• Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23(2), 63–75. https://doi.org/10.1097/HRP.0000000000000075
   PubMed Web of Science ®Google Scholar
• Crooks, D., Tsui, J., Anderson, B., Dossabhoy, S., Herman, D., Liebschutz, J. M., & Stein, M. D. (2015). Differential risk factors for HIV drug and sex risk-taking among non-treatment-seeking hospitalized injection drug users. AIDS and Behavior, 19(3), 405–411. https://doi.org/10.1007/s10461-014-0754-7
   PubMed Web of Science ®Google Scholar
• Cushman, P. A., Liebschutz, J. M., Anderson, B. J., Moreau, M. R., & Stein, M. D. (2016). Buprenorphine initiation and linkage to outpatient buprenorphine do not reduce frequency of injection opiate use following hospitalization. Journal of Substance Abuse Treatment, 68, 68–73. https://doi.org/10.1016/j.jsat.2016.06.003
   PubMed Web of Science ®Google Scholar
• Demaret, I., Lemaître, A., & Ansseau, M. (2012). Staff concerns in heroin-assisted treatment centres. Journal of Psychiatric and Mental Health Nursing, 19(6), 563–567. https://doi.org/10.1111/j.1365-2850.2011.01810.x
   PubMed Web of Science ®Google Scholar
• Edmundson, E., & McCarty, D. (2006). Implementing evidence-based practices for treatment of alcohol and drug disorders. Routledge.
   Google Scholar
• Eibl, J. K., Morin, K., Leinonen, E., & Marsh, D. C. (2017). The state of opioid agonist therapy in Canada 20 Years after federal oversight. Canadian Journal of Psychiatry. Revue canadienne de psychiatrie, 62(7), 444–450. https://doi.org/10.1177/0706743717711167
   PubMed Web of Science ®Google Scholar
• Eydt, E., Glegg, S., Sutherland, C., Meador, K., Trew, M., Perreault, M., Goyer, M.-E., Le Foll, B., Turnbull, J., & Fairbairn, J. (2021). Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. Canadian Medical Association Journal Open, 9(1), E115–E124. https://doi.org/10.9778/cmajo.20200021
   Google Scholar
• Ferri, M., Davoli, M., & Perucci, C. A. (2011). Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database System Review, (12), CD003410. https://doi.org/10.1002/14651858.CD003410.pub4
   PubMed Web of Science ®Google Scholar
• Fischer, B., Pang, M., & Tyndall, M. (2019). The opioid death crisis in Canada: Crucial lessons for public health. The Lancet. Public Health, 4(2), E81–E82. https://doi.org/10.1016/S2468-2667(18)30232-9
   PubMed Web of Science ®Google Scholar
• Fonseca, J., Chang, A., & Chang, F. (2018). Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in Southwestern Ontario. The Journal of Rural Health : Official Journal of the American Rural Health Association and the National Rural Health Care Association, 34(1), 23–30. https://doi.org/10.1111/jrh.12264
   PubMed Web of Science ®Google Scholar
• Gouvernement du Québec (MSSS). (2018). Prévenir, réduire et traiter les conséquences associées à la consommation de substances psychoactives, à la pratique des deux de hasard et d’argent et à l’utilisation d’internet: Plan d’action interministériel en dépendance 2018-2028 (Report No. 18-804-02W). La Direction des communications du ministère de la Santé et des Services sociaux. https://publications.msss.gouv.qc.ca/msss/fichiers/2018/18-804-02W.pdf
   Google Scholar
• Groves, R. M., Presser, S., & Dipko, S. (2004). The role of topic interest in survey participation decisions. Public Opinion Quarterly, 68(1), 2–31. https://doi.org/10.1093/poq/nfh002
   Web of Science ®Google Scholar
• Kilmer, B., Taylor, J., Caulkins, J. P., Mueller, P. A., Ober, A. J., Pardo, B., Smart, R., Strang, L., & Reuter, P. (2018). Considering heroin-assisted treatment and supervised drug consumption sites in the United States. RAND Corporation. https://www.rand.org/pubs/research_reports/RR2693.html
   Google Scholar
• Lasnier, B., Brochu, S., Boyd, N., & Fischer, B. (2010). A heroin prescription trial: Case studies from Montreal and Vancouver on crime and disorder in the surrounding neighbourhoods. The International Journal on Drug Policy, 21(1), 28–35. https://doi.org/10.1016/j.drugpo.2009.04.003
   PubMed Web of Science ®Google Scholar
• Leclerc, P., Vandal, A. C., Fall, A., Bruneau, J., Roy, É., Brissette, S., Archibald, C., Arruda, N., & Morissette, C. (2014). Estimating the size of the population of persons who inject drugs in the island of Montréal, Canada, using a six-source capture-recapture model. Drug and Alcohol Dependence, 142, 174–180. https://doi.org/10.1016/j.drugalcdep.2014.06.022
   PubMed Web of Science ®Google Scholar
• March, J. C., Oviedo-Joekes, E., Perea-Milla, E., Carrasco, F., & Pepsa, t. (2006). Controlled trial of prescribed heroin in the treatment of opioid addiction. Journal of Substance Abuse Treatment, 31(2), 203–211. https://doi.org/10.1016/j.jsat.2006.04.007
   PubMed Web of Science ®Google Scholar
• Mills, K. L., Teesson, M., Ross, J., & Darke, S. (2007). The impact of post-traumatic stress disorder on treatment outcomes for heroin dependence. Addiction, 102(3), 447–454. https://doi.org/10.1111/j.1360-0443.2006.01711.x
   PubMed Web of Science ®Google Scholar
• Nosyk, B., Guh, D. P., Bansback, N. J., Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Meikleham, E., Schechter, M. T., & Anis, A. H. (2012). Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ : Canadian Medical Association Journal = journal de l'Association medicale canadienne, 184(6), E317–E328. https://doi.org/10.1503/cmaj.110669
   PubMed Web of Science ®Google Scholar
• O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020). Retention of patients in opioid substitution treatment: A systematic review. PLoS One, 15(5), e0232086. https://doi.org/10.1371/journal.pone.0232086
   PubMed Web of Science ®Google Scholar
• Ober, A. J., Taylor, J., Iguchi, M. Y., & Caulkins, J. P. (2018). Acceptability of heroin-assisted treatment and supervised drug consumption sites to address the opioid crises in the United States: Key informant perspectives. RAND Corporation. https://www.rand.org/pubs/working_papers/WR1260.html
   Google Scholar
• Oviedo-Joekes, E., Guh, D., Brissette, S., Marchand, K., MacDonald, S., Lock, K., Harrison, S., Janmohamed, A., Anis, A. H., Krausz, M., Marsh, D. C., & Schechter, M. T. (2016). Hydromorphone compared with diacetylmorphine for long-term opioid Dependence: A Randomized Clinical Trial. JAMA Psychiatry, 73(5), 447–455. https://doi.org/10.1001/jamapsychiatry.2016.0109
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes, E., MacDonald, S., Boissonneault, C., & Harper, K. (2021). Take home injectable opioids for opioid use disorder during and after the COVID-19 pandemic is in urgent need: A case study. Substance Abuse Treatment, Prevention, and Policy, 16(1), 22–27. https://doi.org/10.1186/s13011-021-00358-x
   PubMed Web of Science ®Google Scholar
• Paillé, P., & Mucchielli, A. (2012). L'analyse qualitative en sciences humaines et sociales. Armand Colin. https://doi.org/10.3917/arco.paill.2012.01
   Google Scholar
• Perneger, T. V., Giner, F., Del Rio, M., & Mino, A. (1998). Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ (Clinical Research ed.), 317(7150), 13–18. https://doi.org/10.1136/bmj.317.7150.13
   PubMedGoogle Scholar
• Perreault, M., Goyer, M. E., Archambault, L., Laurendeau, M., Rainville, L.-F., Rabouin, D., & Cohen, J. (2020). Guide d’information et d’orientation pour une offre de traitement par agonistes opioïdes injectable au Québec. Institut Universitaire sur les Dépendances. https://taoinjectable.com/2020/03/12/guide-dinformation-et-dorientation-pour-une-offre-de-traitement-par-agonistes-opioides-injectable-au-quebec/
   Google Scholar
• Plaza, A., Joekes, E. O., & March, J. C. (2007). Nursing in an intravenous heroin prescription treatment. Journal of Addictions Nursing, 18 (1), 13–20. https://doi.org/10.1080/10884600601174425
   Web of Science ®Google Scholar
• Resiak, D., Mpofu, E., & Rothwell, R. (2021). Sustainable Harm Reduction Needle and Syringe Programs for People Who Inject Drugs: A Scoping Review of Their Implementation Qualities. Sustainability, 13(5), 2834.
   Google Scholar
• Salvador, J. G., Sussman, A. L., Takeda, M. Y., Katzman, W. G., Balasch, M. M., & Katzman, J. G. (2020). Barriers to and recommendations for take-home naloxone distribution: Perspectives from opioid treatment programs in New Mexico. Harm Reduction Journal, 17(1), 31–38. https://doi.org/10.1186/s12954-020-00375-2
   PubMed Web of Science ®Google Scholar
• Simpson, L. (2017). The obstacles to implementing supervised injection services in Ottawa, Ontario [Master’s thesis, University of Ottawa]. uO Research Theses 2011. https://ruor.uottawa.ca/handle/10393/36953
   Google Scholar
• Smith, P., Favril, L., Delhauteur, D., Vander Laenen, F., & Nicaise, P. (2019). How to overcome political and legal barriers to the implementation of a drug consumption room: an application of the policy agenda framework to the Belgian situation. Addiction Science & Clinical Practice, 14(1).
   PubMed Web of Science ®Google Scholar
• Strang, J., & Gossop, M. (1996). Heroin prescribing in the British system: Historical review. European Addiction Research, 2(4), 185–193. https://doi.org/10.1159/000259131
   Google Scholar
• Strang, J., Groshkova, T., Uchtenhagen, A., van den Brink, W., Haasen, C., Schechter, M. T., Lintzeris, N., Bell, J., Pirona, A., Oviedo-Joekes, E., Simon, R., & Metrebian, N. (2015). Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction†. The British Journal of Psychiatry : The Journal of Mental Science, 207(1), 5–14. https://doi.org/10.1192/bjp.bp.114.149195
   PubMed Web of Science ®Google Scholar
• Strike, C., & Watson, T. M. (2019). Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. International Journal of Drug Policy, 71, 178–182.
   PubMed Web of Science ®Google Scholar
• Tsui, J. I., Burt, R., Thiede, H., & Glick, S. N. (2018). Utilization of buprenorphine and methadone among opioid users who inject drugs. Substance Abuse, 39(1), 83–88. https://doi.org/10.1080/08897077.2017.1363844
   PubMed Web of Science ®Google Scholar
• Wells, C., Dolcine, B., & Frey, N. (2019). Programs for the treatment of opioid addiction: An enviornmental scan. Canadian Agency for Drugs and Techonologies in Health (CADTH). https://cadth.ca/sites/default/files/es/es0335-programs-for-treatment-opioid-addiction-in-Canada.pdf
   Google Scholar
• Winstanley, E. L., Clark, A., Feinberg, J., & Wilder, C. M. (2016). Barriers to implementation of opioid overdose prevention programs in Ohio. Substance Abuse, 37(1), 42–46. https://doi.org/10.1080/08897077.2015.1132294
   PubMed Web of Science ®Google Scholar